Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766853 | 1.00 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL882468 | 0.92 | F2R (0.85) | F2RKMT2A | |
| SCHEMBL18025116 | 0.90 | F2R (0.82) | F2RKMT2A | |
| SCHEMBL10069461 | 0.89 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL10069475 | 0.86 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL882721 | 0.85 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL882806 | 0.85 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL10069477 | 0.85 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL10069483 | 0.85 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL10069462 | 0.85 | F2R (1.00) | F2RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130743-B2 | Heterocyclic ligands of PAR1 and methods of use | MARQUETTE UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200270224-A1 | Heterocyclic Ligands of PAR1 and Methods of Use | MARQUETTE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270224-A1 | Heterocyclic Ligands of PAR1 and Methods of Use | F2R, F2RL1, PLAT | F2R 1/4885KMT2A 4132/4885 |
| US-11130743-B2 | Heterocyclic ligands of PAR1 and methods of use | F2R, F2RL1, PLAT | F2R 1/4885KMT2A 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.